• Xlumena

  Participated · Series C · Dec 2013

  Xlumena develops the AXIOS family of endoscopic stents and delivery systems for interventional endoscopy. Its core product, the AXIOS Stent and Delivery System, is a fully-covered, dual-flanged stent delivered under endoscopic ultrasound guidance to create secure drainage pathways between the gastrointestinal tract and the common bile duct, gallbladder or pseudocyst. The HOT AXIOS variant incorporates cautery into the delivery system, enabling access and stent delivery in a single device. The AXIOS system obtained a CE mark in Europe in 2012 and is available in a select number of centers; devices have been used to treat acute cholecystitis, biliary inflammation and pancreatic pseudocysts. The company intends to use the $25M Series C proceeds to expand global commercialization of the AXIOS family and to bring its platform to the U.S. interventional endoscopy community. Xlumena is led by President and CEO Greg Patterson, and Third Point’s Jason Hong will join the board in conjunction with the financing. Xlumena is a Mountain View, California–based company that develops advanced therapeutic devices for interventional endoscopists and endoscopic surgeons. Its product portfolio includes the NAVIX™ Access Device (FDA‑cleared) and the AXIOS™ Stent and Delivery System (CE marked), along with other devices in various stages of development. The company was founded in 2008 by Kenneth Binmoeller, MD, and Michael Allen, who serves as President and CEO. Management says recent financing will support market expansion in the U.S. and Europe. Xlumena has raised $19M in total financing to date. In conjunction with the latest raise, two investors will join the company’s board.

• Amaranth Medical

  Participated · Series B · Oct 2013

  Amaranth Medical is a privately held medical device company that developed the FORTITUDE bioresorbable scaffold, designed to provide the strength of metal stents without leaving a permanent implant. Its lead product line includes a non‑drug‑eluting FORTITUDE scaffold previously evaluated in a 13‑patient study and a planned drug‑eluting FORTITUDE intended for further clinical evaluation. Results from the initial study, presented at TCT, suggested the scaffold maintained mechanical integrity with late lumen loss comparable to bare metal stents. The company announced an equity investment from Boston Scientific to advance an international clinical study, pursue a CE Mark application, and support development of a next‑generation FORTITUDE scaffold with thinner struts. Amaranth planned to begin enrolling a second cohort in 2014 to evaluate the drug‑eluting scaffold. The company is headquartered in Mountain View, California, with research and manufacturing operations in Singapore and at its Silicon Valley headquarters, and is led by CEO Kamal Ramzipoor. Prior investors named include Charter Life Sciences, Bio*One Capital, Philip Private Equity, DCP Management and Venstar Capital. Amaranth Medical is a Mountain View, California-based medical device company that has created a novel technology platform for the development and manufacturing of fully bioresorbable scaffolds. Led by Kamal Ramzipoor, General Manager and Chief Technical Officer, the company has research and manufacturing operations in Singapore and at its Silicon Valley headquarters. Its lead product is FORTITUDE™, a bioresorbable scaffold intended for treating coronary artery disease. The company intends to use the funds to develop the upcoming CE Mark clinical trial of FORTITUDE. Amaranth closed a $20m Series B financing to advance these clinical and development activities. The financing involved both new and existing investors, reflecting continued support for its platform.

• Mirabilis Medical

  Participated · Series A · Jun 2013

  Mirabilis Medica develops proprietary high-intensity focused ultrasound (HIFU) technology as a non-invasive treatment for uterine fibroids. The company is a women’s healthcare developer focused on commercializing its HIFU platform. It intends to use the new capital to advance research and development toward commercialization. Mirabilis is conducting clinical studies outside of the United States. The company was founded in 2004 and is led by newly appointed CEO Jens U. Quistgaard, a medical device entrepreneur. The recent financing activity reflects efforts to fund ongoing R&D and clinical progress.

• Minimally invasive devices

  Participated · Series B · Jun 2013

  Minimally Invasive Devices (MID) develops FloShield, a tool that prevents laparoscope fogging and contamination by actively protecting and flushing the lens during surgery. The technology eliminates the need to remove the laparoscope for cleaning or defogging, maintaining surgical flow. FloShield protects against condensation, smoke and debris and can flush the lens if it becomes dirty. The product is sold in the US and in 10 countries overseas. MID was founded by laparoscopic surgeon Dr. Wayne Poll and is based in Columbus, Ohio. The company has taken on outside financing to support working capital and continued growth. Minimally Invasive Devices, Inc. develops and manufactures the FloShield™ laparoscopic vision system, a device that attaches to modern HD vision systems to prevent obscuration of the optics and avoid interruption during surgery. The company is led by founder and CEO Wayne Poll and is based in Columbus, Ohio. It raised an additional $2.5M in Series B financing to support its commercial and clinical efforts. The funds are intended for sales and marketing, clinical studies, generation of outcomes data and additional product development. Prior investors Canaan Partners and Charter Life Sciences had previously invested $9M. The company’s product enables laparoscopic procedures to continue without removing the scope for cleaning. Minimally Invasive Devices produces the FDA‑approved FloShield™ laparoscopic vision system, which attaches to HD camera systems and uses an air curtain to form an invisible protective barrier over the lens. The system is augmented by Flo‑X, a biocompatible surfactant designed to flush the lens inside the body if needed. The company says its products allow surgeons to operate without loss of vision and without lens removal. Minimally Invasive Devices intends to use new capital to establish a direct sales unit, expand manufacturing operations, develop complementary products and generate additional data to support system efficacy. The company is led by founder and CEO Wayne Poll, M.D., and is based in Columbus, Ohio. Minimally Invasive Devices develops surgical products to improve laparoscopic visibility, led by its FloShield device that prevents liquid from obstructing a laparoscope tip. The company is preparing a next-generation FloShield, an access system for the product, and a compatible liquid cleaning solution. MID has a distribution deal with CareFusion and is seeking a European distributor, and hopes to receive regulatory approval to sell FloShield in the EU around mid-2011. The latest funding will support these product launches and hiring (the company currently has 10 employees and plans to add another sales support worker). MID has refocused away from a previously planned kidney stone removal tool to concentrate on laparoscopic surgery products to increase acquisition appeal. Financially, the company raised $1.35 million last year for earlier development, has raised more than $1.5 million in the current equity round, and has raised about $7 million since its 2007 founding.

No current team members are available.